Emicizumab-kxwh and Feiba NF

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Using anti-inhibitor coagulant complex together with emicizumab may increase the risk of blood clots, which can lead to serious complications such as stroke, pulmonary embolism (blockage of pulmonary artery), heart attack, heart failure, collapse, and kidney failure. In addition, there have been reports of a rare but serious condition called thrombotic microangiopathy (TMA) that results in blood clots forming in small vessels such as those found in the brain and kidneys. Manifestations of TMA include low platelet count, low red blood cell count (anemia), bleeding, bruising, drowsiness, confusion, seizures, and kidney failure. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact, or you may need a dose adjustment or more frequent monitoring to safely use both medications. You should seek immediate medical attention if you experience potential signs and symptoms of blood clots such as chest pain; shortness of breath; coughing up blood; blood in the urine; sudden loss of vision; and pain, redness, or swelling in your arm or leg. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: Coadministration of emicizumab with activated prothrombin complex concentrate (aPCC) may increase the risk of thrombosis. Cases of thrombotic microangiopathy (TMA) and other thrombotic events have been reported when cumulative amounts greater than 100 U/kg/24 hours of aPCC was administered for 24 hours or more to patients receiving emicizumab prophylaxis. In two emicizumab efficacy trials, TMA was reported in 1.6% (3/189) and 8.3% of patients (3/36) who received at least one dose of aPCC. Evidence of improvement was seen within one week following discontinuation of aPCC. Thrombotic events were reported in 1.1% (2/189) and 5.6% of patients (2/36) who received at least one dose of aPCC. No thrombotic event required anticoagulation therapy, and evidence of improvement or resolution was seen within one month following discontinuation of aPCC.

MANAGEMENT: Close monitoring is recommended when activated prothrombin complex concentrate must be used during emicizumab prophylaxis. Immediately discontinue aPCC and suspend dosing of emicizumab if clinical symptoms, imaging, and/or laboratory findings consistent with TMA or thromboembolism occur, and manage as clinically indicated. Consider the benefits and risks of resuming emicizumab prophylaxis following complete resolution of TMA or thromboembolism on a case-by-case basis.

Emicizumab-kxwh

Generic Name: emicizumab

Brand name: Hemlibra, Hemlibra 105 mg/07 mL, Hemlibra 60 mg/04 mL

Synonyms: Emicizumab

What is Emicizumab-kxwh?

Feiba NF

Generic Name: anti-inhibitor coagulant complex

Brand name: Feiba, Feiba VH Immuno, Autoplex T, Feiba NF

Synonyms: Feiba NF (Intravenous), FEIBA NF

What is Feiba NF?